atorvastatin 40 mg
1 INDICATIONS AND USAGE Atorvastatin calcium tablets are indicated: • To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia o Hypertriglyceridemia Atorvastatin calcium tablets are an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): • To reduce the risk of: o Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. o MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. o Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. • As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: o Adults with primary hyperlipidemia. o Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia. • As an adjunct to diet for the treatment of adults with: o Primary dysbetaliproteinemia. o Hypertriglyceridemia.
sandoz inc
ROUND YELLOW HLA 40
Related Pills
atorvastatin 80 mg
sandoz inc
atorvastatin 40 mg
sandoz inc
atorvastatin 10 mg
sandoz inc
atorvastatin 20 MG Oral Tablet
Sandoz Inc
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING Atorvastatin calcium tablets are supplied as follows: 10 mg, light yellow, dappled, glossy, round biconvex film-coated tablets, debossed with “HLA 10” on one side. Bottles contain desiccant. NDC 0781-5381-31, bottle of 30 tablets NDC 0781-5381-92, bottle of 90 tablets NDC 0781-5381-01, bottle of 100 tablets NDC 0781-5381-10, bottle of 1000 tablets NDC 0781-5381-34, bottle of 3000 tablets 20 mg, light yellow, dappled, glossy, round biconvex film-coated tablets, debossed with “HLA 20” on one side. Bottles contain desiccant. NDC 0781-5382-31, bottle of 30 tablets NDC 0781-5382-92, bottle of 90 tablets NDC 0781-5382-01, bottle of 100 tablets NDC 0781-5382-10, bottle of 1000 tablets NDC 0781-5382-34, bottle of 3000 tablets 40 mg, light yellow, dappled, glossy, round biconvex film-coated tablets, debossed with “HLA 40” on one side. Bottles contain desiccant. NDC 0781-5384-31, bottle of 30 tablets NDC 0781-5384-92, bottle of 90 tablets NDC 0781-5384-01, bottle of 100 tablets NDC 0781-5384-10, bottle of 1000 tablets NDC 0781-5384-22, bottle of 2000 tablets 80 mg, light yellow, dappled, glossy, oval biconvex film-coated tablets, debossed with “HLA 80” on one side. Bottles contain desiccant. NDC 0781-5388-31, bottle of 30 tablets NDC 0781-5388-92, bottle of 90 tablets NDC 0781-5388-01, bottle of 100 tablets NDC 0781-5388-10, bottle of 1000 tablets Storage Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, light-resistant container.
More pills like ROUND HLA 40